<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Oral PrEP vs LAI-PrEP: Circular Cascade Comparison</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: 'Helvetica Neue', Arial, sans-serif;
            background: #ffffff;
            padding: 30px;
        }

        .container {
            max-width: 1900px;
            margin: 0 auto;
            background: white;
            padding: 40px;
        }

        h1 {
            color: #1a202c;
            font-size: 2.6em;
            margin-bottom: 15px;
            text-align: center;
            font-weight: 700;
        }

        .subtitle {
            color: #4a5568;
            font-size: 1.3em;
            text-align: center;
            margin-bottom: 50px;
        }

        .comparison-grid {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 80px;
            margin-top: 40px;
        }

        .circular-panel {
            display: flex;
            flex-direction: column;
            align-items: center;
        }

        .panel-header {
            text-align: center;
            margin-bottom: 35px;
            padding: 25px;
            border-radius: 12px;
            width: 100%;
        }

        .panel-header.oral {
            background: linear-gradient(135deg, #d1fae5 0%, #a7f3d0 100%);
            border: 3px solid #059669;
        }

        .panel-header.lai {
            background: linear-gradient(135deg, #fef3c7 0%, #fde68a 100%);
            border: 3px solid #f59e0b;
        }

        .panel-header h2 {
            font-size: 2em;
            margin-bottom: 10px;
        }

        .panel-header.oral h2 {
            color: #065f46;
        }

        .panel-header.lai h2 {
            color: #92400e;
        }

        .panel-subtitle {
            font-size: 1.15em;
            color: #374151;
            font-weight: 600;
        }

        .circular-container {
            position: relative;
            width: 700px;
            height: 700px;
            margin-top: 20px;
        }

        /* Center circle - Critical barrier */
        .center-circle {
            position: absolute;
            top: 50%;
            left: 50%;
            transform: translate(-50%, -50%);
            width: 260px;
            height: 260px;
            background: linear-gradient(135deg, #dc2626 0%, #991b1b 100%);
            border-radius: 50%;
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: center;
            box-shadow: 0 10px 40px rgba(220, 38, 38, 0.4);
            border: 6px solid #7f1d1d;
            z-index: 10;
        }

        .center-title {
            color: white;
            font-size: 1.5em;
            font-weight: 700;
            text-align: center;
            margin-bottom: 8px;
            line-height: 1.3;
        }

        .center-subtitle {
            color: white;
            font-size: 1em;
            text-align: center;
            opacity: 0.95;
            margin-bottom: 12px;
        }

        .center-stat {
            background: rgba(0,0,0,0.3);
            color: white;
            padding: 10px 20px;
            border-radius: 20px;
            font-size: 1.3em;
            font-weight: 700;
        }

        /* Process nodes */
        .process-node {
            position: absolute;
            width: 125px;
            height: 125px;
            border-radius: 50%;
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: center;
            font-weight: 600;
            font-size: 0.9em;
            color: white;
            text-align: center;
            padding: 12px;
            box-shadow: 0 4px 15px rgba(0,0,0,0.2);
            border: 3px solid rgba(255,255,255,0.3);
            transition: transform 0.3s ease;
        }

        .process-node:hover {
            transform: scale(1.1);
        }

        .node-label {
            font-size: 1em;
            margin-bottom: 4px;
        }

        .node-rate {
            font-size: 0.75em;
            opacity: 0.9;
            font-weight: 400;
            margin-top: 4px;
        }

        .node-retention {
            font-size: 1.2em;
            font-weight: 700;
            background: rgba(0,0,0,0.2);
            padding: 3px 8px;
            border-radius: 10px;
            margin-top: 3px;
        }

        /* Oral PrEP nodes */
        .oral-node1 { top: 15px; left: 50%; transform: translateX(-50%); background: linear-gradient(135deg, #059669 0%, #047857 100%); }
        .oral-node2 { top: 70px; right: 90px; background: linear-gradient(135deg, #10b981 0%, #059669 100%); }
        .oral-node3 { top: 200px; right: 30px; background: linear-gradient(135deg, #34d399 0%, #10b981 100%); }
        .oral-node4 { bottom: 200px; right: 30px; background: linear-gradient(135deg, #6ee7b7 0%, #34d399 100%); }
        .oral-node5 { bottom: 70px; right: 90px; background: linear-gradient(135deg, #6ee7b7 0%, #34d399 100%); }
        .oral-node6 { bottom: 15px; left: 50%; transform: translateX(-50%); background: linear-gradient(135deg, #a7f3d0 0%, #6ee7b7 100%); color: #065f46; }
        .oral-node7 { bottom: 70px; left: 90px; background: linear-gradient(135deg, #d1fae5 0%, #a7f3d0 100%); color: #065f46; }
        .oral-node8 { bottom: 200px; left: 30px; background: linear-gradient(135deg, #d1fae5 0%, #a7f3d0 100%); color: #065f46; }
        .oral-node9 { top: 200px; left: 30px; background: linear-gradient(135deg, #10b981 0%, #059669 100%); }

        /* LAI PrEP nodes */
        .lai-node1 { top: 15px; left: 50%; transform: translateX(-50%); background: linear-gradient(135deg, #9333ea 0%, #7e22ce 100%); }
        .lai-node2 { top: 70px; right: 90px; background: linear-gradient(135deg, #a855f7 0%, #9333ea 100%); }
        .lai-node3 { top: 200px; right: 30px; background: linear-gradient(135deg, #6366f1 0%, #4f46e5 100%); }
        .lai-node4 { bottom: 200px; right: 30px; background: linear-gradient(135deg, #3b82f6 0%, #2563eb 100%); }
        .lai-node5 { bottom: 70px; right: 90px; background: linear-gradient(135deg, #10b981 0%, #059669 100%); }
        .lai-node6 { bottom: 15px; left: 50%; transform: translateX(-50%); background: linear-gradient(135deg, #14b8a6 0%, #0d9488 100%); }
        .lai-node7 { bottom: 70px; left: 90px; background: linear-gradient(135deg, #06b6d4 0%, #0891b2 100%); }
        .lai-node8 { bottom: 200px; left: 30px; background: linear-gradient(135deg, #0ea5e9 0%, #0284c7 100%); }

        /* Barriers */
        .barrier {
            position: absolute;
            background: #f3f4f6;
            border: 3px solid #9ca3af;
            border-radius: 10px;
            padding: 12px 15px;
            font-size: 0.85em;
            font-weight: 600;
            color: #374151;
            box-shadow: 0 2px 8px rgba(0,0,0,0.1);
            max-width: 140px;
            text-align: center;
            z-index: 5;
        }

        .barrier-critical {
            background: #fef2f2;
            border-color: #dc2626;
            color: #991b1b;
        }

        .barrier1 { top: 150px; right: -15px; }
        .barrier2 { bottom: 150px; right: -15px; }
        .barrier3 { bottom: 170px; left: -25px; }
        .barrier4 { top: 170px; left: -25px; }

        /* Connection circles */
        .connection-circle {
            position: absolute;
            top: 50%;
            left: 50%;
            transform: translate(-50%, -50%);
            border: 3px dashed #cbd5e0;
            border-radius: 50%;
            z-index: 1;
        }

        .circle1 { width: 520px; height: 520px; }
        .circle2 { width: 420px; height: 420px; opacity: 0.5; }

        /* Population legend */
        .population-legend {
            margin-top: 30px;
            padding: 20px;
            background: #f9fafb;
            border-radius: 10px;
            border: 2px solid #e5e7eb;
        }

        .legend-title {
            font-size: 1.2em;
            font-weight: 700;
            color: #1f2937;
            margin-bottom: 15px;
            text-align: center;
        }

        .legend-grid {
            display: grid;
            grid-template-columns: repeat(3, 1fr);
            gap: 15px;
        }

        .legend-item {
            background: white;
            padding: 12px;
            border-radius: 8px;
            border: 2px solid #e5e7eb;
            text-align: center;
        }

        .legend-pop {
            font-weight: 600;
            color: #374151;
            font-size: 0.95em;
            margin-bottom: 5px;
        }

        .legend-rate {
            font-size: 1.3em;
            font-weight: 700;
            color: #dc2626;
        }

        .legend-note {
            font-size: 0.8em;
            color: #6b7280;
            margin-top: 3px;
        }

        /* Key insights */
        .insights-section {
            margin-top: 50px;
            padding: 35px;
            background: linear-gradient(135deg, #ede9fe 0%, #ddd6fe 100%);
            border-radius: 15px;
            border: 3px solid #7c3aed;
        }

        .insights-title {
            font-size: 1.8em;
            color: #5b21b6;
            text-align: center;
            margin-bottom: 25px;
            font-weight: 700;
        }

        .insights-grid {
            display: grid;
            grid-template-columns: 1fr 1fr;
            gap: 25px;
        }

        .insight-card {
            background: white;
            padding: 25px;
            border-radius: 12px;
            box-shadow: 0 4px 15px rgba(0,0,0,0.1);
        }

        .insight-card h3 {
            color: #5b21b6;
            font-size: 1.3em;
            margin-bottom: 12px;
        }

        .insight-card p {
            color: #4a5568;
            line-height: 1.6;
            font-size: 1.05em;
        }

        .stat-highlight {
            background: #fef3c7;
            color: #92400e;
            padding: 3px 8px;
            border-radius: 6px;
            font-weight: 700;
        }

        @media (max-width: 1600px) {
            .comparison-grid {
                grid-template-columns: 1fr;
                gap: 60px;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>Oral PrEP vs. LAI-PrEP: Circular Cascade Comparison</h1>
        <p class="subtitle">Identifying Critical Barriers Across the Prevention Continuum</p>

        <div class="comparison-grid">
            <!-- LEFT: Oral PrEP Circular Model -->
            <div class="circular-panel">
                <div class="panel-header oral">
                    <h2>ORAL PrEP CASCADE</h2>
                    <p class="panel-subtitle">Same-Day Start Available • Daily Pill</p>
                </div>

                <div class="circular-container">
                    <div class="connection-circle circle1"></div>
                    <div class="connection-circle circle2"></div>

                    <!-- Center: Critical Drop-off Point -->
                    <div class="center-circle">
                        <div class="center-title">ADHERENCE &<br>PERSISTENCE</div>
                        <div class="center-subtitle">Critical Barrier</div>
                        <div class="center-stat">40-48% Lost</div>
                    </div>

                    <!-- Process nodes with retention rates -->
                    <div class="process-node oral-node1">
                        <div class="node-label">1. Awareness</div>
                        <div class="node-retention">100%</div>
                        <div class="node-rate">MSM: 85-90%<br>Trans: 50-70%</div>
                    </div>

                    <div class="process-node oral-node2">
                        <div class="node-label">2. Willingness</div>
                        <div class="node-retention">90-95%</div>
                        <div class="node-rate">Interested</div>
                    </div>

                    <div class="process-node oral-node3">
                        <div class="node-label">3. Eligibility</div>
                        <div class="node-retention">85-90%</div>
                        <div class="node-rate">Meet criteria</div>
                    </div>

                    <div class="process-node oral-node4">
                        <div class="node-label">4. Access</div>
                        <div class="node-retention">75-85%</div>
                        <div class="node-rate">Insurance/appt</div>
                    </div>

                    <div class="process-node oral-node5">
                        <div class="node-label">5. Linkage</div>
                        <div class="node-retention">75-80%</div>
                        <div class="node-rate">Attend appt</div>
                    </div>

                    <div class="process-node oral-node6">
                        <div class="node-label">6. Prescription</div>
                        <div class="node-retention">75-80%</div>
                        <div class="node-rate">Same-day start</div>
                    </div>

                    <div class="process-node oral-node7">
                        <div class="node-label">7. Initiation</div>
                        <div class="node-retention">70-78%</div>
                        <div class="node-rate">Fill Rx, start</div>
                    </div>

                    <div class="process-node oral-node8">
                        <div class="node-label">8. Adherence</div>
                        <div class="node-retention">52-62%</div>
                        <div class="node-rate">6 mo retention</div>
                    </div>

                    <div class="process-node oral-node9">
                        <div class="node-label">9. Persistence</div>
                        <div class="node-retention">52%</div>
                        <div class="node-rate">Continued use</div>
                    </div>

                    <!-- Barriers -->
                    <div class="barrier barrier1">
                        Insurance Coverage
                    </div>
                    <div class="barrier barrier2 barrier-critical">
                        Daily Pill Burden
                    </div>
                    <div class="barrier barrier3">
                        PrEP Stigma
                    </div>
                    <div class="barrier barrier4">
                        Provider Access
                    </div>
                </div>

                <!-- Population-specific data -->
                <div class="population-legend">
                    <div class="legend-title">Population-Specific Drop-off Rates (Oral PrEP)</div>
                    <div class="legend-grid">
                        <div class="legend-item">
                            <div class="legend-pop">MSM (General)</div>
                            <div class="legend-rate">38-40%</div>
                            <div class="legend-note">Most persistent</div>
                        </div>
                        <div class="legend-item">
                            <div class="legend-pop">Trans Men</div>
                            <div class="legend-rate">43.9%</div>
                            <div class="legend-note">Moderate loss</div>
                        </div>
                        <div class="legend-item">
                            <div class="legend-pop">Trans Women</div>
                            <div class="legend-rate">70%</div>
                            <div class="legend-note">Highest attrition</div>
                        </div>
                        <div class="legend-item">
                            <div class="legend-pop">Black/Latino MSM</div>
                            <div class="legend-rate">44-52%</div>
                            <div class="legend-note">Structural barriers</div>
                        </div>
                        <div class="legend-item">
                            <div class="legend-pop">Young MSM (&lt;30)</div>
                            <div class="legend-rate">44-69%</div>
                            <div class="legend-note">Age-related loss</div>
                        </div>
                        <div class="legend-item">
                            <div class="legend-pop">Cisgender Women</div>
                            <div class="legend-rate">48-56%</div>
                            <div class="legend-note">Variable retention</div>
                        </div>
                    </div>
                </div>
            </div>

            <!-- RIGHT: LAI-PrEP Circular Model -->
            <div class="circular-panel">
                <div class="panel-header lai">
                    <h2>LAI-PrEP CASCADE</h2>
                    <p class="panel-subtitle">Mandatory 2-8 Week Bridge • Bimonthly Injection</p>
                </div>

                <div class="circular-container">
                    <div class="connection-circle circle1"></div>
                    <div class="connection-circle circle2"></div>

                    <!-- Center: Critical Drop-off Point -->
                    <div class="center-circle">
                        <div class="center-title">BRIDGE<br>NAVIGATION</div>
                        <div class="center-subtitle">2-8 Weeks</div>
                        <div class="center-stat">47.1% Lost</div>
                    </div>

                    <!-- Process nodes with retention rates -->
                    <div class="process-node lai-node1">
                        <div class="node-label">1. Awareness</div>
                        <div class="node-retention">100%</div>
                        <div class="node-rate">LAI-PrEP exists</div>
                    </div>

                    <div class="process-node lai-node2">
                        <div class="node-label">2. Willingness</div>
                        <div class="node-retention">95%</div>
                        <div class="node-rate">67% prefer inj</div>
                    </div>

                    <div class="process-node lai-node3">
                        <div class="node-label">3. Eligibility</div>
                        <div class="node-retention">90%</div>
                        <div class="node-rate">Meet criteria</div>
                    </div>

                    <div class="process-node lai-node4">
                        <div class="node-label">4. Prescription</div>
                        <div class="node-retention">85%</div>
                        <div class="node-rate">Provider Rx</div>
                    </div>

                    <div class="process-node lai-node5">
                        <div class="node-label">6. Injection</div>
                        <div class="node-retention">45%</div>
                        <div class="node-rate">First dose</div>
                    </div>

                    <div class="process-node lai-node6">
                        <div class="node-label">7. Persistence</div>
                        <div class="node-retention">37%</div>
                        <div class="node-rate">81-83% of those<br>who initiate</div>
                    </div>

                    <div class="process-node lai-node7">
                        <div class="node-label">8. Retention</div>
                        <div class="node-retention">37%</div>
                        <div class="node-rate">Continued care</div>
                    </div>

                    <div class="process-node lai-node8">
                        <div class="node-label">5. BRIDGE</div>
                        <div class="node-retention" style="background: rgba(220, 38, 38, 0.3);">52.9%</div>
                        <div class="node-rate">Navigate 2-8 wks</div>
                    </div>

                    <!-- Barriers -->
                    <div class="barrier barrier1 barrier-critical">
                        HIV Testing Requirements
                    </div>
                    <div class="barrier barrier2 barrier-critical">
                        Appointment Scheduling
                    </div>
                    <div class="barrier barrier3 barrier-critical">
                        Insurance Authorization
                    </div>
                    <div class="barrier barrier4">
                        Lead-in Period
                    </div>
                </div>

                <!-- Population-specific data -->
                <div class="population-legend">
                    <div class="legend-title">Bridge Period Attrition (All Populations)</div>
                    <div class="legend-grid">
                        <div class="legend-item">
                            <div class="legend-pop">Overall</div>
                            <div class="legend-rate">47.1%</div>
                            <div class="legend-note">Lost pre-initiation</div>
                        </div>
                        <div class="legend-item">
                            <div class="legend-pop">Successfully Navigate</div>
                            <div class="legend-rate">52.9%</div>
                            <div class="legend-note">Receive first injection</div>
                        </div>
                        <div class="legend-item">
                            <div class="legend-pop">Post-Initiation</div>
                            <div class="legend-rate">81-83%</div>
                            <div class="legend-note">Excellent retention</div>
                        </div>
                        <div class="legend-item" style="grid-column: 1 / -1; background: #fef2f2;">
                            <div class="legend-pop" style="color: #991b1b;">Critical Finding</div>
                            <div class="legend-note" style="font-size: 0.95em; margin-top: 8px;">
                                The bridge period creates a structural barrier that eliminates nearly half of motivated users <strong>before</strong> they can experience LAI-PrEP's superior persistence (81-83% vs oral's 52%)
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <!-- Key Insights Section -->
        <div class="insights-section">
            <div class="insights-title">🔬 Critical Insights: Where Barriers Occur</div>
            <div class="insights-grid">
                <div class="insight-card">
                    <h3>Oral PrEP: Post-Initiation Adherence Problem</h3>
                    <p>The critical barrier occurs <strong>after prescription and initiation</strong>. Patients can start same-day, but <span class="stat-highlight">40-48% discontinue</span> due to daily pill burden, side effects, and adherence challenges. Trans women face <span class="stat-highlight">70% discontinuation</span>—the highest of any group.</p>
                </div>

                <div class="insight-card">
                    <h3>LAI-PrEP: Pre-Initiation Access Problem</h3>
                    <p>The critical barrier occurs <strong>before the first injection</strong>. Conservative initiation protocols create a mandatory 2-8 week bridge period where <span class="stat-highlight">47.1% are lost</span> to HIV testing, insurance authorization, and appointment coordination. Those who successfully navigate show <span class="stat-highlight">81-83% persistence</span>.</p>
                </div>

                <div class="insight-card">
                    <h3>The Implementation Paradox</h3>
                    <p>LAI-PrEP was designed to solve oral PrEP's adherence problem, and it succeeds: <span class="stat-highlight">81-83%</span> retention vs. <span class="stat-highlight">52%</span> for oral. However, it creates a new problem—nearly half of motivated users are eliminated by structural barriers before experiencing this advantage.</p>
                </div>

                <div class="insight-card">
                    <h3>Population Disparities</h3>
                    <p>Oral PrEP shows dramatic population differences: trans women (<span class="stat-highlight">70%</span> loss), young Black MSM (<span class="stat-highlight">69%</span> loss), and those without insurance face highest attrition. LAI-PrEP's bridge period affects all populations equally (<span class="stat-highlight">47.1%</span>)—it's a structural, not behavioral, barrier.</p>
                </div>
            </div>
        </div>
    </div>
</body>
</html>